Newsroom
Strive to Deliver Breakthroughs
-
June 02, 2020
Harbour BioMed Receives Chinese Regulatory Approval of IND Application to Begin Seamless Phase 2/3 Clinical Trial of HBM9161 in Graves' Ophthalmopathy
HBM9161 Receives Its Fourth IND Approval for Clinical Trials in China Cambridge, MA, Rotterdam, NL, Suzhou, CN (June 1, 2020) – Ha...
View more -
May 04, 2020
Utrecht University, Erasmus Medical Center and Harbour BioMed Researchers Report Discovery of Antibody that Blocks Novel Coronavirus SARS-CoV-2 Infection in Cells
Research Published in Nature Communications is Initial Step Towards Developing Fully Human Antibody Therapeutics and Diagnostics for Respiratory Disease COVID-...
View more -
April 22, 2020
Harbour BioMed Announces First Patient Dosing of Phase 1b/2a Study of Anti-FcRn Batoclimab for Treating Neuromyelitis Optica Spectrum Disorder
·First anti-FcRn PoC study for the treatment of NMOSD ·Anti-FcRn antibody with potential to become a portfolio-in-a-product Cambr...
View more -
April 16, 2020
Harbour BioMed Receives Chinese Regulatory Approval of IND Application to Begin Seamless Phase 2/3 Clinical Trial of HBM9161 in Immune Thrombocytopenia
Anti-FcRn antibody has potential to become portfolio-in-a-product; ITP trial is the first of several to study safety and efficacy in autoimmune disorders &n...
View more -
April 03, 2020
Harbour BioMed Appoints Ms. Jun Zuo as Vice President and Head of Regulatory Affairs
Harbour BioMed (HBM) today announced the appointment of Mrs. Jun Zuo as Vice President and Head of Regulatory Affairs, effective March 31st, 2020. Mrs. Zuo wil...
View more -
March 12, 2020
Harbour BioMed Raises $75 Million Series B+ Venture Capital Financing To Accelerate Its Innovative Pipeline
New funding drives advancement of next generation biologic therapeutics pipeline Cambridge, MA; Rotterdam, The Netherlands & Suzhou, CN &...
View more -
March 06, 2020
Mount Sinai and Harbour BioMed Collaborate to Advance Novel Biotherapies for the Treatment of Cancer and Coronavirus COVID-19
Collaboration combines Harbour BioMed’s proprietary H2L2 Harbour Mice® platform for fully human monoclonal antibody generation with Mount Sinai&...
View more -
February 28, 2020
Harbour BioMed Receives U.S. FDA IND Approval for Phase 2 Clinical Trial and Orphan Drug Designation for Anti-PD-L1 Monoclonal Antibody, HBM9167
Cambridge, MA; Rotterdam, NL; Suzhou, CN February 27, 2020 Harbour BioMed (HBM) today announced U.S. Food and Drug Administration (FDA) approval o...
View more -
February 28, 2020
Harbour BioMed Announces U.S. FDA Approval of IND for Its Next Generation anti-CTLA-4 Antibody, HBM4003, to Treat Cancer
First fully human, heavy chain only antibody in human trials has shown potent activity in preclinical studies through differentiated mechanism of action &nb...
View more -
February 21, 2020
Harbour BioMed Announces Completion of Phase 1 Study in China of HBM9161, an Anti-FcRn Antibody
Cambridge, MA, Rotterdam, NL, Suzhou, CN – February 21, 2020 Harbour BioMed (HBM) today announced completion of a Phase 1 study of HBM...
View more
Copyright © 2025 Harbour BioMed. All Rights Reserved
沪公网安备31011502401396号
沪ICP备19015946号-1